Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Begacestat · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Donepezil plus placebo | EXPERIMENTAL | - |
| Donepezil plus begacestat | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Donepezil plus placebo | DRUG | 5- and 10-mg tablets, single dose |
| Donepezil | DRUG | 5- and 10-mg tablets, single dose |
| Begacestat | DRUG | 6 x 50-mg capsules, single dose |
Inclusion Criteria: * Healthy * Men and women of non-childbearing potential * Non smoker or smoker of \<10 cigarettes per day and able to refrain from smoking during study * 18-50 years old Exclusion Criteria: * Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal, endocr...
Begacestat is an investigational small molecule being studied in healthy subjects. It was evaluated in a Phase 1 clinical trial to assess the effects of coadministering Begacestat with donepezil. The drug is not approved and remains in clinical development.
Begacestat is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The company conducted a Phase 1 clinical trial of the drug in healthy volunteers.
Begacestat is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, controlled study in healthy subjects. The drug is investigational and has not been approved.
Begacestat has one completed clinical trial, registered as NCT00959881. This Phase 1 study evaluated the coadministration of Begacestat and donepezil in healthy subjects in the United States. The trial enrolled 47 participants.
No, Begacestat is not the same as donepezil. Begacestat is an investigational small molecule being studied by Pfizer. Donepezil is a separate drug used in the clinical trial to assess the effects of coadministering it with Begacestat.